# DoD Multiple Sclerosis, Clinical Trial Award

Source: https://welltoldgrants.com/grants/ht942524msrpcta-dod-multiple-sclerosis-clinical-trial-award/  
Official notice: https://www.grants.gov/search-results-detail/353635

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 3 awards worth $8.0 million in total. Applications closed on October 7, 2024.

| Field | Value |
|---|---|
| Opportunity number | HT942524MSRPCTA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | October 7, 2024 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 3 |
| Total funding | $8.0 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

The MSRP CTA supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations. The FY24 MSRP CTA offers two funding levels (Refer to Section II.D.5, Funding Restrictions). Only one funding level may be chosen per application and the choice of application category is at the discretion of the applicant. The requested budget at each funding level must be justified and appropriate to the scope of the clinical trial proposed. The following are generalized descriptions of the scope of research appropriate for each funding level: • Funding Level 1 (CTA-FL1) supports small-scale, early-phase, proof-of-principle clinical trials to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this funding level. Preliminary data relevant to the proposed clinical trial, preferably in subjects with MS, are required. • Funding Level 2 (CTA-FL2) supports larger-scale clinical trials at phase 1 or phase 2 that seek to show preliminary evidence of safety or efficacy (i.e., benefit of clinical or paraclinical outcomes) in relevant patient populations. Strong justification should be provided, which could include, but is not limited to, intervention type, trial duration, sample size, outcome measures, assessment tools, and frequency of assessment. Preliminary data relevant to the proposed clinical trial, preferably in subjects with MS, are required. For the purposes of this funding opportunity, Regulatory Agency refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency unless otherwise noted. Key aspects of the FY24 MSRP CTA Award Mechanism: • Clinical Trial Start Date: The proposed clinical trial is expected to begin no later than 12 months after the award date or 18 months after the award date for studies regulated by the Regulatory Agency.

## Questions people ask

### Is HT942524MSRPCTA still open?

No. It closed on October 7, 2024. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoD Multiple Sclerosis, Clinical Trial Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoD Multiple Sclerosis, Clinical Trial Award?

Closed October 7, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $8.0 million in total across about 3 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.